This inventor holds 3 USPTO granted patents, plus 1 CIPO patent and 2 EPO patents. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2014-2020.
Company Filing History:
Years Active: 2014-2020
Title: Arisa Maeda: Innovator in Pharmaceutical Technology
Introduction
Arisa Maeda is a prominent inventor based in Osaka, Japan. She has made significant contributions to the field of pharmaceutical technology, particularly in the development of innovative oral preparations. With a total of 3 patents to her name, Maeda's work focuses on enhancing the efficacy and stability of pharmaceutical formulations.
Latest Patents
One of her latest patents is a tablet designed to show high stability of active ingredients, specifically potassium-competitive acid blockers and acetylsalicylic acid. This invention provides a tablet that contains an inner core, which is an enteric-coated tablet with acetylsalicylic acid, and an outer layer that includes a potassium-competitive acid blocker free of enteric coating. Another notable patent is an oral preparation that effectively masks the bitter taste of pioglitazone and its salts. This preparation contains pioglitazone or a salt thereof along with alkali metal chloride, ensuring a more palatable experience for patients.
Career Highlights
Arisa Maeda is currently associated with Takeda Pharmaceutical Company Limited, where she continues to innovate and contribute to the pharmaceutical industry. Her work has been instrumental in developing formulations that improve patient compliance and therapeutic outcomes.
Collaborations
Throughout her career, Maeda has collaborated with esteemed colleagues such as Kazuhiro Okochi and Yuichi Sugiyama. These collaborations have further enhanced her research and development efforts in the pharmaceutical sector.
Conclusion
Arisa Maeda's contributions to pharmaceutical technology exemplify her dedication to improving drug formulations. Her innovative patents reflect her commitment to enhancing patient care through effective and stable medications.
